INVEST substudies

Design and patient characteristics

M. Keltai, J. A. Johnson, P. R. Kowey, L. D. Ried, M. Tueth

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The INternational VErapamil SR/trandolapril STudy (INVEST) will provide a large database of information. Proposed substudies for analysis include ambulatory blood pressure monitoring (ABPM), depression, genotyping, atrial fibrillation, electrocardiogram (ECG), echocardiography, renal dysfunction, diabetes, and cardiac care cost estimate. This paper reviews the design and status of several of the INVEST substudies. The ABPM substudy will obtain objective blood pressure recordings during daily life masked to both the patient and the investigator. Ambulatory blood pressure monitoring is an especially useful technology because of the role of nocturnal hypertension and circadian blood pressure irregularities in the development of hypertensive disease. The depression substudy, which enrolled 2,393 patients in the United States, will report quality-of-life (QOL) data, including information regarding energy and fatigue. The genotyping substudy will provide genomic DNA samples from approximately 15,000 patients in the United States, including Puerto Rico. Many candidate genes will be examined for polymorphisms that may predict outcomes and/or responses to various treatments.

Original languageEnglish
JournalClinical Cardiology
Volume24
Issue number11 SUPPL.
Publication statusPublished - 2001

Fingerprint

trandolapril
Ambulatory Blood Pressure Monitoring
Verapamil
Blood Pressure
Puerto Rico
Atrial Fibrillation
Fatigue
Echocardiography
Electrocardiography
Quality of Life
Research Personnel
Databases
Hypertension
Technology
Kidney
Costs and Cost Analysis
DNA
Genes

Keywords

  • Ambulatory blood pressure monitoring
  • Atrial fibrillation
  • Depression
  • INVEST substudies
  • Polymorphisms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Keltai, M., Johnson, J. A., Kowey, P. R., Ried, L. D., & Tueth, M. (2001). INVEST substudies: Design and patient characteristics. Clinical Cardiology, 24(11 SUPPL.).

INVEST substudies : Design and patient characteristics. / Keltai, M.; Johnson, J. A.; Kowey, P. R.; Ried, L. D.; Tueth, M.

In: Clinical Cardiology, Vol. 24, No. 11 SUPPL., 2001.

Research output: Contribution to journalArticle

Keltai, M, Johnson, JA, Kowey, PR, Ried, LD & Tueth, M 2001, 'INVEST substudies: Design and patient characteristics', Clinical Cardiology, vol. 24, no. 11 SUPPL..
Keltai M, Johnson JA, Kowey PR, Ried LD, Tueth M. INVEST substudies: Design and patient characteristics. Clinical Cardiology. 2001;24(11 SUPPL.).
Keltai, M. ; Johnson, J. A. ; Kowey, P. R. ; Ried, L. D. ; Tueth, M. / INVEST substudies : Design and patient characteristics. In: Clinical Cardiology. 2001 ; Vol. 24, No. 11 SUPPL.
@article{53a453a34d124458958f1362158229af,
title = "INVEST substudies: Design and patient characteristics",
abstract = "The INternational VErapamil SR/trandolapril STudy (INVEST) will provide a large database of information. Proposed substudies for analysis include ambulatory blood pressure monitoring (ABPM), depression, genotyping, atrial fibrillation, electrocardiogram (ECG), echocardiography, renal dysfunction, diabetes, and cardiac care cost estimate. This paper reviews the design and status of several of the INVEST substudies. The ABPM substudy will obtain objective blood pressure recordings during daily life masked to both the patient and the investigator. Ambulatory blood pressure monitoring is an especially useful technology because of the role of nocturnal hypertension and circadian blood pressure irregularities in the development of hypertensive disease. The depression substudy, which enrolled 2,393 patients in the United States, will report quality-of-life (QOL) data, including information regarding energy and fatigue. The genotyping substudy will provide genomic DNA samples from approximately 15,000 patients in the United States, including Puerto Rico. Many candidate genes will be examined for polymorphisms that may predict outcomes and/or responses to various treatments.",
keywords = "Ambulatory blood pressure monitoring, Atrial fibrillation, Depression, INVEST substudies, Polymorphisms",
author = "M. Keltai and Johnson, {J. A.} and Kowey, {P. R.} and Ried, {L. D.} and M. Tueth",
year = "2001",
language = "English",
volume = "24",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "11 SUPPL.",

}

TY - JOUR

T1 - INVEST substudies

T2 - Design and patient characteristics

AU - Keltai, M.

AU - Johnson, J. A.

AU - Kowey, P. R.

AU - Ried, L. D.

AU - Tueth, M.

PY - 2001

Y1 - 2001

N2 - The INternational VErapamil SR/trandolapril STudy (INVEST) will provide a large database of information. Proposed substudies for analysis include ambulatory blood pressure monitoring (ABPM), depression, genotyping, atrial fibrillation, electrocardiogram (ECG), echocardiography, renal dysfunction, diabetes, and cardiac care cost estimate. This paper reviews the design and status of several of the INVEST substudies. The ABPM substudy will obtain objective blood pressure recordings during daily life masked to both the patient and the investigator. Ambulatory blood pressure monitoring is an especially useful technology because of the role of nocturnal hypertension and circadian blood pressure irregularities in the development of hypertensive disease. The depression substudy, which enrolled 2,393 patients in the United States, will report quality-of-life (QOL) data, including information regarding energy and fatigue. The genotyping substudy will provide genomic DNA samples from approximately 15,000 patients in the United States, including Puerto Rico. Many candidate genes will be examined for polymorphisms that may predict outcomes and/or responses to various treatments.

AB - The INternational VErapamil SR/trandolapril STudy (INVEST) will provide a large database of information. Proposed substudies for analysis include ambulatory blood pressure monitoring (ABPM), depression, genotyping, atrial fibrillation, electrocardiogram (ECG), echocardiography, renal dysfunction, diabetes, and cardiac care cost estimate. This paper reviews the design and status of several of the INVEST substudies. The ABPM substudy will obtain objective blood pressure recordings during daily life masked to both the patient and the investigator. Ambulatory blood pressure monitoring is an especially useful technology because of the role of nocturnal hypertension and circadian blood pressure irregularities in the development of hypertensive disease. The depression substudy, which enrolled 2,393 patients in the United States, will report quality-of-life (QOL) data, including information regarding energy and fatigue. The genotyping substudy will provide genomic DNA samples from approximately 15,000 patients in the United States, including Puerto Rico. Many candidate genes will be examined for polymorphisms that may predict outcomes and/or responses to various treatments.

KW - Ambulatory blood pressure monitoring

KW - Atrial fibrillation

KW - Depression

KW - INVEST substudies

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=0034757971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034757971&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 11 SUPPL.

ER -